Instinct Bio Technical Company
BIOT
Last
$0.37
Day
-4.9%
1y
-96.1%
5y
-96.1%
52w
-99.2%
SPY YTD
+13.3%
XLP
+7.4%
Earnings
—
EMA 21
0.45
EMA 50
1.57
EMA 200
6.07
20d high
-24.7%
5y high
-99.2%
5y range
0th
Positions held
Your positionsBIOT isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-12
Hold
avoid
Signal
Sell
Target
$0.46
Stop
$0.33
Stop distance
10.8%
Target vs last
+24.3%
Fundamentals
| Market cap | $11.20M | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | none | Mean target | — |
| 52w high | $50.00 | 52w low | $0.33 |
Quarterly
No data yet.
Yearly (6y)
| 2024 | 2023 | |
|---|---|---|
| Revenue | $2.8M | $3.4M |
| Op margin | -2.5% | 11.6% |
| Net income | $0.1M | $0.5M |
| Gross margin | 72.4% | 86.7% |
| Gross profit | $2.0M | $3.0M |
| Operating income | -$0.1M | $0.4M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · BIOT Named Authorized Representative for IN01 Cancer Immunotherapy in Japan and China
2026-09-28 · AI agent startup Instinct hits $10 billion valuation following $1 billion round
2026-09-04 · INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives
Price (daily)
Full chart · RSI · MACD · patternsBIOT · daily-12.3% over 14 sessions
Close EMA21 EMA50 EMA200